Effect of intensive blood pressure control on subtypes of mild cognitive impairment and risk of progression from SPRINT study
- PMID: 34826341
- PMCID: PMC9106821
- DOI: 10.1111/jgs.17583
Effect of intensive blood pressure control on subtypes of mild cognitive impairment and risk of progression from SPRINT study
Abstract
Background: To examine the effect of intensive blood pressure control on the occurrence of subtypes of mild cognitive impairment (MCI) and determine the risk of progression to dementia or death.
Methods: Secondary analysis of a randomized trial of community-dwelling adults (≥50 years) with hypertension. Participants were randomized to a systolic blood pressure (SBP) goal of <120 mm Hg (intensive treatment; n = 4678) or <140 mm Hg (Standard treatment; n = 4683). Outcomes included adjudicated MCI, MCI subtype (amnestic, non-amnestic, multi-domain, single domain), and probable dementia. Multistate survival models were used to examine transitions in cognitive status accounting for the competing risk of death.
Results: Among 9361 randomized participants (mean age, 67.9 years; 3332 women [35.6%]), 640 participants met the protocol definition for MCI, with intensive treatment reducing the risk of MCI overall (hazard ratio [HR], 0.81 [95% confidence interval {CI}, 0.69-0.94]), as previously reported. This effect was largely reflected in amnestic subtypes (HR, 0.78 [95% CI, 0.66-0.92]) and multi-domain subtypes (HR, 0.78 [95% CI, 0.65-0.93]). An adjudication of MCI, as compared with normal cognitive function, substantially increased the probability of progressing to probable dementia (5.9% [95% CI: 4.5%-7.7%] vs. 0.6% [95% CI: 0.3%-0.9%]) and to death (10.0% [95% CI: 8.3%-11.9%] vs. 2.3% [95% CI: 2.0%-2.7%]) within 2 years.
Conclusions: Intensive treatment reduced the risk for amnestic and multi-domain subtypes of MCI. An adjudication of MCI was associated with increased risk of progression to dementia and death, highlighting the relevance of MCI as a primary outcome in clinical and research settings.
Keywords: MCI (mild cognitive impairment); blood pressure control; clinical trials.
© 2021 The American Geriatrics Society.
Figures
Comment in
-
Mild cognitive impairment as a clinical and research outcome: Ready for prime time?J Am Geriatr Soc. 2022 May;70(5):1361-1364. doi: 10.1111/jgs.17744. Epub 2022 Mar 16. J Am Geriatr Soc. 2022. PMID: 35293612 Free PMC article. No abstract available.
Similar articles
-
Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial.JAMA Netw Open. 2023 May 1;6(5):e2314443. doi: 10.1001/jamanetworkopen.2023.14443. JAMA Netw Open. 2023. PMID: 37204788 Free PMC article. Clinical Trial.
-
Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment.JAMA Netw Open. 2022 Jan 4;5(1):e2145319. doi: 10.1001/jamanetworkopen.2021.45319. JAMA Netw Open. 2022. PMID: 35089354 Free PMC article.
-
Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial.JAMA. 2019 Feb 12;321(6):553-561. doi: 10.1001/jama.2018.21442. JAMA. 2019. PMID: 30688979 Free PMC article. Clinical Trial.
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. PMID: 32129963 Free Books & Documents. Review.
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
Cited by
-
The association between preserved ratio impaired spirometry (PRISm) and cognitive function among American older adults: the mediating role of systolic blood pressure.BMC Geriatr. 2024 Oct 24;24(1):870. doi: 10.1186/s12877-024-05349-8. BMC Geriatr. 2024. PMID: 39449111 Free PMC article.
-
A genome-wide association meta-analysis of all-cause and vascular dementia.Alzheimers Dement. 2024 Sep;20(9):5973-5995. doi: 10.1002/alz.14115. Epub 2024 Jul 24. Alzheimers Dement. 2024. PMID: 39046104 Free PMC article.
-
Current perspectives on prevention of vascular cognitive impairment and promotion of vascular brain health.Expert Rev Neurother. 2024 Jan-Jun;24(1):25-44. doi: 10.1080/14737175.2023.2273393. Epub 2024 Jan 8. Expert Rev Neurother. 2024. PMID: 37916306 Review.
-
Ascertainment and Statistical Issues for Randomized Trials of Cardiovascular Interventions for Cognitive Impairment and Dementia.Hypertension. 2024 Jan;81(1):45-53. doi: 10.1161/HYPERTENSIONAHA.123.19941. Epub 2023 Sep 21. Hypertension. 2024. PMID: 37732473 Review.
-
Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT.Hypertension. 2023 Jul;80(7):1484-1493. doi: 10.1161/HYPERTENSIONAHA.123.21323. Epub 2023 May 11. Hypertension. 2023. PMID: 37165900 Free PMC article. Clinical Trial.
References
-
- Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med [Internet]. 2014;275:214–228. Available from: http://doi.wiley.com/10.1111/joim.12190 - DOI - PMC - PubMed
-
- Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand [Internet]. 2009;119:252–265. Available from: http://doi.wiley.com/10.1111/j.1600-0447.2008.01326.x - DOI - PubMed
-
- Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology [Internet]. 2011;76:280–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21178097 - PMC - PubMed
-
- Smith EE, Cieslak A, Barber P, Chen J, Chen Y-W, Donnini I, Edwards JD, Frayne R, Field TS, Hegedus J, Hanganu V, Ismail Z, Kanji J, Nakajima M, Noor R, Peca S, Sahlas D, Sharma M, Sposato LA, Swartz RH, Zerna C, Black SE, Hachinski V. Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment. J Am Heart Assoc [Internet]. 2017;6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28476873 - PMC - PubMed
-
- Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L-O, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med [Internet]. 2004;256:240–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15324367 - PubMed
Publication types
MeSH terms
Grants and funding
- UL1 TR000445/TR/NCATS NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- UL1 TR000075/TR/NCATS NIH HHS/United States
- UL1 TR000093/TR/NCATS NIH HHS/United States
- P30 AG049638/AG/NIA NIH HHS/United States
- UL1 TR000003/TR/NCATS NIH HHS/United States
- UL1 TR000050/TR/NCATS NIH HHS/United States
- UL1 RR025755/RR/NCRR NIH HHS/United States
- P30 AG072947/AG/NIA NIH HHS/United States
- R01 AG055606/AG/NIA NIH HHS/United States
- P30 AG021332/AG/NIA NIH HHS/United States
- UL1 TR000433/TR/NCATS NIH HHS/United States
- L30 AG074138/AG/NIA NIH HHS/United States
- HHSN268200900048C/HL/NHLBI NIH HHS/United States
- UL1 TR000005/TR/NCATS NIH HHS/United States
- HHSN268200900040C/HL/NHLBI NIH HHS/United States
- UL1 TR002548/TR/NCATS NIH HHS/United States
- HHSN268200900046C/HL/NHLBI NIH HHS/United States
- P30 GM103337/GM/NIGMS NIH HHS/United States
- UL1 TR001064/TR/NCATS NIH HHS/United States
- UL1 RR025752/RR/NCRR NIH HHS/United States
- UL1 RR025771/RR/NCRR NIH HHS/United States
- HHSN268200900049C/HL/NHLBI NIH HHS/United States
- HHSN268200900047C/HL/NHLBI NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- UL1 TR000073/TR/NCATS NIH HHS/United States
- UL1 TR000002/TR/NCATS NIH HHS/United States
- UL1 TR000105/TR/NCATS NIH HHS/United States
- UL1 RR024134/RR/NCRR NIH HHS/United States
- UL1 TR003142/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
